EFFECT OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS ON ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH MEMBRANOUS NEPHROPATHY

Authors:

Abstract:

The purpose of the study was to evaluate whether adding sodium-glucose cotransporter 2 inhibitors to standard therapy improves endothelial dysfunction in adults with idiopathic membranous nephropathy. In this prospective observational study, 42 phospholipase A2 receptor–positive patients were followed for 6 months and compared by treatment status (sodium-glucose cotransporter 2 inhibitor + standard therapy vs standard therapy alone); endothelial function (endothelium-dependent vasodilation and endothelium-independent vasodilation) and biomarkers (endothelin-1, and intercellular adhesion molecule-1, high-sensitivity C-reactive protein) were assessed together with urinary albumin-to-creatinine ratio. Add-on sodium-glucose cotransporter 2 inhibitor therapy was associated with a greater improvement in endothelium-dependent vasodilation (p=0.032), a larger reduction in albuminuria (p<0.001), and more pronounced decreases in endothelin-1 (p<0.001), intercellular adhesion molecule-1 (p=0.002), and high-sensitivity C-reactive protein (p=0.036), while endothelium-independent vasodilation and intima–media thickness did not differ significantly between groups. These findings suggest potential endothelial and antiproteinuric benefits of sodium-glucose cotransporter 2 inhibition in membranous nephropathy.

Keywords:

membranous nephropathy sodium-glucose cotransporter 2 inhibitors endothelial dysfunction endothelium-dependent vasodilation endothelin-1 intercellular adhesion molecule-1 albuminuria

References:

1. Choi C-I. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents. Molecules. 2016; 21(9):1136. https://doi.org/10.3390/molecules21091136.
2. Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2017 Jun 7;12(6):983-997. doi: 10.2215/CJN.11761116.
3. Del Vecchio L, Peiti S, Pucci Bella G, Locatelli F. SGLT2 Inhibitors in Glomerulonephritis: Beyond Nephroprotection? Journal of Clinical Medicine. 2025; 14(10):3533. https://doi.org/10.3390/jcm14103533.
4. Dou L, Jourde-Chiche N. Endothelial Toxicity of High Glucose and its by-Products in Diabetic Kidney Disease. Toxins. 2019; 11(10):578. https://doi.org/10.3390/toxins11100578.
5. Ismailova Sh, Mammadzada A, Muradova S, Huseynova N, Mammadova A, Kazimli A, et al. Impact of empagliflozin on endothelial function in non-diabetic chronic kidney disease. Azerbaijan Medical Journal. 2025; 1: 34-38, doi:10.34921/amj.2025.1.006.
6. Koirala A, Singh A, Geetha D. Recurrence of Glomerular Diseases (GN) After Kidney Transplantation: A Narrative Review. Journal of Clinical Medicine. 2025; 14(18):6686. https://doi.org/10.3390/jcm14186686.
7. Lim WH, Shingde M, Wong G. Recurrent and de novo Glomerulonephritis After Kidney Transplantation. Front Immunol. 2019 Aug 14;10:1944. doi: 10.3389/fimmu.2019.01944.
8. Mammadzada AY, Ismayilova ShG, Ibrahimova ShS, Huseynova NI, Huseyn LA. World of Medicine and Biology. 2023; 3(85): 129-132. doi:10.26724/2079-8334-2023-3-85-129-132.
9. Prabhu RR, Vojjala N, Prabhahar A, Bharati J, Gorsi U, Rana P, Arora S, Ramachandran R. Assessment of Endothelial Dysfunction in Patient with Phospholipase A2 Receptor (PLA2R)-Positive Primary Membranous Nephropathy in Remission: TH-PO599. Journal of the American Society of Nephrology. 2024; 35. 10.1681/ASN.20245me64hb7.
10. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018; 61: 2108–2117. https://doi.org/10.1007/s00125-018-4670-7.

Publication:

«World of Medicine and Biology» Vol. 22 No. 1 (2026) , с. 82-86
УДК 616.61-002.6-085.244

DOI:

https://doi.org/10.26724/2079-8334-2026-1-95-82-86